



Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

All legal disclaimers applicable to the journal apply to this production process as well.

Monaldi Arch Chest Dis 2024 [Online ahead of print]

To cite this Article:

Mohapatra MM, Vemuri MB, Saka VK, et al. **Prevalence and predictors of suboptimal peak inspiratory flow rates in the management of chronic obstructive pulmonary disease.** *Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2024.3210

 ©The Author(s), 2024
Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



Prevalence and predictors of suboptimal peak inspiratory flow rates in the management of chronic obstructive pulmonary disease

Madhusmita Mohanty Mohapatra,¹ Mahesh Babu Vemuri,² Vinod Kumar Saka,¹
Pratap Upadhyaya,¹ Vishnukanth Govindharaj¹

¹Department of Pulmonary Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry; ²Department of Pulmonary Medicine, All India Institute of Medical Sciences, Bibinagar, Hyderabad, India

Correspondence: Mahesh Babu Vemuri, Department of Pulmonary Medicine, All India Institute of Medical Sciences, Bibinagar, Hyderabad, India. E-mail: vmahesh8497@gmail.com

Contributions: all the authors made a substantial intellectual contribution, read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Conflict of interest: the authors declare that they have no competing interests.

Ethics approval and consent to participate: the study protocol was approved by the Institute Scientific Committee, Institute ethics committee (JIP/IEC/2021/063),

Informed consent: written informed consent was obtained from all participants before enrollment in the study

Funding: supported and funded by TB Association of India.

Availability of data and materials: available from the corresponding author upon request.

Abstract

This cross-sectional study aimed to investigate the role of peak inspiratory flow rate (PIFR) in the management of inhalation therapy for patients with chronic obstructive pulmonary disease (COPD). Conducted in the Department of Pulmonary Medicine at a tertiary care institute from July 2021 to January 2022, this study included a total of 351 patients who were clinically diagnosed with stable COPD and currently receiving inhaler therapy.

Participants underwent comprehensive assessments that included demographic data collection, the use of the ABCD assessment tool to evaluate disease severity, the COPD Assessment Test (CAT) for quality of life measurement, and assessments for adherence to inhaler therapy and inhaler technique proficiency. The primary focus was on determining the prevalence of suboptimal PIFR and identifying associated demographic and clinical factors.

The results indicated that 45% of the patients exhibited suboptimal PIFR, which is critical for effective medication delivery in COPD management. Analysis revealed several significant predictors of suboptimal PIFR: female gender, lower CAT scores, the type of inhaler device used, and a Modified Medical Research Council grade of ≥ 2 , which indicates increased levels of breathlessness.

These findings underscore the importance of assessing PIFR in COPD patients to ensure effective drug delivery. The study suggests that personalized inhaler device prescriptions tailored to individual PIFR can enhance treatment efficacy and improve overall management outcomes for COPD patients. By addressing factors contributing to suboptimal PIFR, healthcare providers can optimize inhalation therapy and ultimately improve patient quality of life.

Key words: COPD, dry powder inhaler, inhaler devices, inspiratory capacity.

Introduction

Chronic obstructive pulmonary disease (COPD) is considered the third leading cause of death with mortality of about 3 million annually and expected to rise to 5.4 million deaths annually by 2060 [1]. The global prevalence of COPD stands at 10.3% (95% confidence interval (CI) 8.2%,12.8%) [2]. The number of COPD cases in India increased from 28.1 million (27.0-29.2) in 1990 to 55.3 million (53.1-57.6) in 2016 with an increase in prevalence from 3.3% (3.1-3.4) to 4.2% (4.0-4.4) [3].

Treatment of COPD involves the use of beta-2-agonists, muscarinic antagonists and inhaled corticosteroid which are delivered through specialized devices such as metered-dose inhalers (MDIs), dry powder inhalers (DPIs) and soft mist inhalers (SMIs). The use of these inhaler devices requires coordination techniques. MDIs require more complex coordination technique for drug delivery than DPIs. However, effective delivery of medication also requires the patient's inspiratory effort to overcome internal resistance present in each device. This internal resistance offered by the flow channel of the device is set by the manufacturer to provide the energy required to disaggregate the drug formulation and allow effective delivery to the lungs. All inhaler devices do not have the same internal resistance. The internal resistance of the device along with the inspiratory flow of the patient allows the powder to disaggregate [4].

Peak inspiratory flow rate (PIFR) measures the patient's inspiratory effort and is used to assess a patient's ability to generate an adequate inspiratory flow rate to overcome internal resistance. As per literature, a PIFR < 60L/min in COPD is considered ineffective for inhaled medications [5,6]. Spirometer can also measure the inspiratory flow rate using surrogates like maximal inspiratory pressure and correlates well with the PIFR. But spirometry-based measurements in a busy outpatient setup can be cumbersome. The internal resistance of each inhaler device varies, with MDIs having the least internal resistance while DPIs having the maximum internal resistance. Since COPD patients have hyperinflation and less respiratory muscle effort, it is important to evaluate the inspiratory capacity of COPD patients before prescribing inhaler devices. PIFR is also affected by factors like age, gender, race, ethnicity, and BMI. Hence, we conducted this study with intent to determine the prevalence and factors predicting suboptimal PIFR value in a tertiary care hospital.

Materials and Methods

This cross-sectional study was conducted in the department of Pulmonary Medicine of a tertiary care institute from July 2021 to January 2022. The study protocol was approved by the Institute Scientific Committee, Institute ethics committee (JIP/IEC/2021/063), and written informed consent was obtained from all participants before enrollment in the study. Patients aged more than 40 years who were clinically diagnosed with stable COPD and on inhaler therapy attending the outpatient /clinic were included in the study. Stable COPD patients who were on inhaled medications but not on systemic steroids during the last three months and without exacerbation were recruited. Patients who had active tuberculosis, undergone thoracic surgery, bronchial asthma, interstitial lung disease, pregnant women and using nebulizers for inhaled medications were excluded from the study. The demographic data of patients were noted down in a prerequisite proforma. The MMRC dyspnea score and COPD assessment score (CAT score) were noted down. Spirometry was done by a Jager Masterscreen PFT machine (Care Fusion Ltd., Basingstoke, UK) to assess severity of airflow obstruction. Post bronchodilator forced expiratory value for 1 second (FEV1) value were recorded after administering 400mcg of salbutamol by a metered dose inhaler. Based on post FEV1 value, patient airflow limitation was graded as per GOLD stages 1, 2, 3 and 4. History of previous exacerbation of COPD in terms of hospitalization or use of oral corticosteroid in the last one year were also evaluated at the same time. Patients were then categorized into groups A, B, C, and D based on MMRC grade, CAT score and number of exacerbations using the refined ABCD assessment tool. Information regarding inhaler medication adherence was collected using Test of adherence to inhaler questionnaire (TAI). An erratic and deliberate poor adherent behavioral pattern was defined by the presence of scores < 45 and good adherence with score of 50. A technical error in using inhaler device was observed and using inhaler technique checklist of NHS Liverpool Clinical Commissioning Group present in the public domain they were scored 0-3 if patients had poor inhaler technique, 4-5 moderate inhaler technique and 6-7 for good inhaler technique. The patient's adequate drug delivery capacity was determined by measuring the peak inspiratory flow rate. PIFR was done by asking patients to inhale as quickly as possible with the InCheck DIAL device, which is a handheld inspiratory flow measurement device after a complete exhalation. The highest PIFR value for each patient was considered after three attempts of deep

inspiration. Since DPI devices have the highest resistance amongst devices, a PIFR of < 60L/min was considered low and >60L/min is considered as normal as per literature. The PIFR value of each patient was then matched with the type of inhaler device used by the patient to see whether the correct drug delivery device had been prescribed.

Statistical analysis: Data entry was done using REDcap Software and the statistical analysis was done using Statistical Package for the Social Sciences (SPSS), version 19 (IBM Corporation, Armonk, New York, USA). The normality of continuous data was assessed by the Kolmogorov-Smirnov test. Depending on the distribution of the data, the variables were described as mean with standard deviation or median and interquartile range. Categorical data were described using frequencies and percentages. The prevalence was estimated with 95% confidence interval. The outcome variable was compared with the independent variables using the Chi-square test for significance. The outcome measures were reported with 95% confidence interval and statistical analysis was considered to be significant at 5% level of significance ($p < 0.05$). Multiple regression analysis was done to evaluate the effect of multiple factors on low PIFR.

Sample size: Assuming the prevalence of low peak inspiratory flow rate to be around 32% as per study done by Sharma et al, with absolute precision of 5%, confidence interval of 95% and attrition of 10% sample size calculated was 368 [7].

Results

A total of 368 patients were screened for the study, and 351 patients were recruited following inclusion criteria, while 6 patients were excluded as they were on nebulizers, 11 patients had bronchial asthma. The mean age of our study population was 61.28 ± 9.05 years, with majority of them belonging to age range of 50-69 years. Males were the predominant gender in our study subjects. The majority of our patients were nonsmokers and had history of biomass fuel exposure. The BMI of our study participants were in the range of 18.5-22.9 and most of them had at least primary education (Table 1). Prevalence of suboptimal PIFR was found in 159 COPD patients (45%) (Figure 1).

The distribution of different clinical scores in COPD patients was also analyzed. The majority of the study participants were found to have a CAT score of <10 with a good inhaler technique score of >3. However, the Test for adherence to inhaler score was found to be similar with most

of the COPD patients having good adherence to treatment. Most of the COPD patients belonged to the A group of refined ABCD assessment test (Table 2).

The predictors for suboptimal PIFR in COPD patients were also analyzed. Female gender was found to be an important predictor for suboptimal PIFR and was found to be statistically significant compared to male gender (p value-0.001). Patients with a BMI range of 18.5-22.9 were found to have suboptimal PIFR in COPD patients as compared to patients with lower BMI. Patients who had lower CAT score performed better as their PIFR were in the optimal range compared to those with higher CAT score. Most of the patients in our study were using DPI compared to MDI. However, since MDI have low internal resistance, suboptimal PIFR was seen in only 15.4% and in patients using DPI suboptimal PIFR was seen in 47.7%, which was statistically significant. In MMRC grading, most of the patients had MMRC grade ≥ 2 (55.7%) in the suboptimal PIFR group, and it was found to be statistically significant compared to that of patients with MMRC grade 0-1 (p -value-0.05) (Table 3).

Discussion

In our study, we found that around 45% of COPD patients had suboptimal PIFR. A similar prevalence was noted in studies done by other investigators [8-10]. The prevalence was found to be higher when the PIFR threshold was changed to <45 L/min for all ranges of resistance [10]. The suboptimal PIFR was found in 4 patients of COPD when a low resistance device like MDI was used while 155 COPD patients had lower PIFR when DPI which is a medium resistance device, was used by them. However, a suboptimal peak inspiratory flow rate (PIFR) in one device cannot be used to predict the suboptimal PIFR value for other devices. This implies that a patient who does not receive an adequate dose of medication from one device may switch to another device. Therefore, the choice of inhaler device should be customized based on the patient's individual PIFR value for various resistance ranges. The majority of our patients using medium resistance devices had optimal PIFR (52.3%) and suboptimal PIFR (47.7%), while patients using low resistance devices had optimal PIFR (84.6%) and suboptimal PIFR (15.4%).

Based on various clinical scores, the majority of our COPD patients, about (83%) had a CAT score of <10 score and belonged to the group A of ABCD assessment test. This is because majority of our subjects who were recruited for the study were stable patients. However,

majority of our COPD patients did not have good inhaler technique scores with a score of less than 3 points despite having good adherence to medications.

Using multiple regression analysis, the various clinical factors which were responsible for low PIFR were evaluated. Female gender was found to be significant clinical predictor of low PIFR in COPD patients confirming the findings of prior studies [7,11,12]. Majority of our patients with suboptimal PIFR were of older age although there was no statistical difference in age groups among patients with optimal PIFR. The weak strength of respiratory muscles and the presence or absence of intrinsic positive end-expiratory pressure could potentially contribute to suboptimal peak inspiratory flow rate (PIFR) in older individuals. Nevertheless, no significant difference was observed in body mass index (BMI) between the two groups, which is consistent with the results of previous studies.

The CAT score was observed to be higher among suboptimal PIFR group compared to the optimal group in our study suggesting that higher symptom burden and poor health status could be responsible for impaired inspiratory capacity. This is in concordance with the study by Loh et al., where there was higher CAT score in suboptimal group compared to the optimal group [13,14]. Study done by Sharma et al. however suggested that there was no difference in CAT score between the two groups. This could be due to the distribution of study subjects and the two groups and the level of severity of the enrolled participants [7].

The inhaler technique score of patients between both the groups was compared, and there was significant difference in the score between suboptimal and optimal groups with majority of patients belonging to suboptimal group had poor inhaler technique scores. Hua et al. in his study demonstrated that training and orientation of COPD patients is required to improve inhaler technique and poor inhaler technique was associated with low PIFR which was in accordance with our study [15].

The majority of our patients with suboptimal PIFR belonged to the A category (122 patients) of refined ABCD assessment tool for COPD. This tool is mainly based on patient's symptoms and history of exacerbations. This was followed by majority of patients belonging to the B category. In our study majority of patients with optimal PIFR also belonged to A category, followed by B category of the refined ABCD assessment tool. However, in our study, there was a significant difference between patients with optimal and suboptimal PIFR groups in the C category of

ABCD assessment tool with more patients in the C category had low PIFR. This may be because these patients have more symptoms and exacerbation leading to decreased inspiratory capacity and suboptimal PIFR. A study by Parekh AB et al. suggested that inspiratory capacity of A and B category is lower than that of C category and this difference is statistically significant with $p < 0.001$ [16]. The majority of our study participants had GOLD stage 3 followed by GOLD stage 2. This may be because majority of our patients belonged to old age with decreased capacity to perform spirometry and poor health status.

In our study, MMRC grading of 0-1 is present in 82.6%, and 43.1% are having suboptimal PIFR whereas MMRC ≥ 2 grading is present in 17.3% of patients among which 55.7% are having suboptimal PIFR. This indicates that PIFR values may vary according to the dyspnea scale (suboptimal PIFR is present in patients with MMRC grade ≥ 2) but results are found to be not statistically significant (p -value-0.05). Similar to our study, MMRC grading was not significant in other studies [7,15,17].

The spirometric parameters of FEV1% predicted, and FEV1/FVC ratio showed no difference between the cohort. The absence of difference in FEV1% between both the cohort was also found in the study conducted by Sharma G et al.[6] However, there was significant difference in FVC% predicted between the suboptimal and optimal groups. This was found to be in agreement with study by Mahler DA et al. and Duarte A et al. [12,18].

Limitations: Our study has few limitations. It was a single centered cross-sectional study. The PIFR value was measured against a single DPI device, while other high and medium internal resistance device was not checked to assess the performance of PIFR. In our study, we have taken PIFR of < 60 L/min as a suboptimal value from previous studies, but recent studies have shown that even with PIFR > 30 L/min, adequate clinical effects can be obtained.

Conclusions

Female gender, higher CAT score, high mMRC grade and poor inhaler technique are important predictors of suboptimal PIFR. The majority of our study subjects with suboptimal PIFR. Hence, it is imperative to perform a simple routine measurement of PIFR value so that personalized inhaler device can be prescribed so that the patient may benefit from adequate therapy.

References

1. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modeling analysis. *Lancet Respir Med* 2022;10:447-58.
2. World Health Organization. Projections of mortality and causes of death, 2016 and 2060. Available from: <https://colinmathers.com/2022/05/10/projections-of-global-deaths-from-2016-to-2060/>. Accessed: July 2023.
3. India State-Level Disease Burden Initiative CRD Collaborators. The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990-2016. *Lancet Glob Health* 2018;6:e1363-74.
4. Newman SP. Principles of metered-dose inhaler design. *Respir Care* 2005;50:1177-90.
5. Janssens W, Vandenberghe P, Hardeman E, et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. *Eur Respir J* 2008;31:78-83.
6. Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. *J Aerosol Med Pulm Drug Deliv* 2014;27:103-9.
7. Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. *Chronic Obstr Pulm Dis* 2017;4:217-24.
8. Harb HS, Laz NI, Rabea H, et al. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients. *Eur J Pharm Sci* 2020;147:105298.
9. Ghosh S, Pleasants RA, Ohar JA, et al. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. *Int J Chron Obstruct Pulmon Dis* 2019;14:585-95.
10. Loh CH, Lovings TM, Ohar JA. Low inspiratory flow rates predict COPD and all-cause readmissions, in A23. Understanding and reducing copd rehospitalizations. Available from: https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A1125.
11. Ghosh S, Pleasants RA, Donohue JF, et al. Device-specific suboptimal peak inspiratory flow rates are common in chronic obstructive pulmonary disease, in B33. COPD: maintenance therapy. 2018, *Am J Respir Crit Care Med* 2008;197:A3034.

12. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. *J Aerosol Med Pulm Drug Deliv* 2013;26:174-9.
13. Loh CH, Ohar JA. Personalization of device therapy—prime time for peak inspiratory flow rate. *Chronic Obstr Pulm Dis* 2017;4:172-6.
14. Loh CH, Peters SP, Lovings TM, Ohar JA. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. *Ann Am Thorac Soc* 2017;14:1305-11.
15. Hua JL, Ye XF, Du CL, et al. Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma. *BMC Pulm Med* 2021;21:302.
16. Parekh AB, Kshatriya MR, Khara NV, et al. Inspiratory capacity in chronic obstructive pulmonary disease: a measure of hyperinflation and relation with other parameters – a cross-sectional study. *Indian J Respir Care* 2018;7:93-6.
17. Samarghandi A, Ioachimescu OC, Qayyum R. Association between peak inspiratory flow rate and hand grip muscle strength in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. *PLoS One* 2020;15:e0227737.
18. Duarte A, Tung L, Hsu ES, et al. Spirometry measurement of peak inspiratory flow identifies suboptimal use of dry powder inhalers in ambulatory patients with COPD. *Chronic Obstr Pulm Dis* 2019;6:246-55.

Table 1. Sociodemographic characteristics of COPD patients included in the study (N=351).

Characteristic	Categories	n	%
Age group in years	40-49	23	7
	50-59	123	35
	60-69	126	36
	≥70	79	23
Gender	Male	257	73
	Female	94	27
Education	No formal education	103	29
	Class 1-5	125	36
	Class 6-10	113	32
	Class 11 & above	10	3
BMI (in kg/m ²)	<18.5	109	31
	18.5-22.9	174	50
	23.0-24.9	37	11
	≥25.0	31	9
Smoking status	Nonsmoker	192	55
	Smoker	141	39
	Ex-smoker	18	5
Biomass exposure	No	149	42
	Yes	202	58
Type of inhaler use	MDI	25	7
	DPI	326	93
FEV1/FVC [MEAN(SD)]	-	56.51(9.88)	
FVC [MEAN(SD)]	-	55.33(12.68)	
FEV1 [MEAN(SD)]	-	44.28(15.57)	

Table 2. Distribution of COPD patients included in the study by different clinical scores (N=351)

Characteristic	Categories	n	%
CAT score	Score <10)	293	83
	Score >10)	58	17
Test for Adherence to Inhaler Score	<45 (poor adherence)	169	48
	> 50 (good adherence)	182	52
Inhaler technique score	<3 (poor inhaler technique)	200	57
	>3 (good inhaler technique)	151	43
COPD ABCD assessment	A	286	81.5
	B	47	13.4
	C	17	4.8
	D	1	0.3

Table 3. Predictors of suboptimal PIFR among COPD patients included in the study (N=351).

Characteristic	Categories	PIFR <60 L/min		PIFR ≥60 L/min		Unadjusted PR ⁺	P-value	Adjusted PR ⁺	95% C.I
		N	%	N	%				
Age group in years	40-49	9	39.1	14	60.9	Ref			
	50-59	55	44.7	68	55.3	1.14	0.632		
	60-69	50	39.7	76	60.3	1.01	0.960		
	≥70	45	56.9	34	43.0	1.45	0.177		
Gender	Male	104	40.5	153	59.5	Ref			
	Female	55	58.5	39	41.5	1.45	0.001	1.31	1.05-1.66
Education	No formal education	49	47.6	54	52.4	Ref			
	Class 1-5	64	51.2	61	48.8	1.08	0.587		
	Class 6-10	42	36.3	71	62.0	0.78	0.117		
	Class 11 & above	4	40.0	6	60.0	0.84	0.665		
Smoking status	Non-smoker	92	47.9	100	52.1	Ref			
	Smoker	61	43.3	80	56.7	0.90	0.404		
	Ex-smoker	6	33.3	12	66.7	0.69	0.288		
Biomass exposure	No	70	47.0	79	53.1	Ref			
	Yes	89	44.1	113	55.9	0.94	0.592		
Inhaler type	DPI	155	47.7	170	52.3	Ref		Ref	
	MDI	4	15.4	22	84.6	0.32	0.015	0.10	0.14-0.73
CAT score	<10	126	43.0	167	57.0	Ref		Ref	
	>10	33	56.9	25	43.1	1.32	0.035	1.20	0.83-1.74
Adherence to inhaler score	<45	76	45.0	93	55.0	Ref			
	>50	83	45.6	99	54.4	1.01	0.905		
Inhaler technique score	<3	130	65.0	70	35.0	Ref		Ref	
	>3	29	19.2	122	80.8	0.29	<0.001	0.39	0.28-0.55
MMRC grading	0-1	125	43.1	165	56.9	Ref			
	≥2	34	55.7	27	44.3	1.29	0.05		
COPD ABCD assessment	A	122	42.7	164	57.3	Ref		Ref	
	B	26	55.3	21	44.7	1.30	0.079	1.38	0.89-2.10
	C	11	64.7	6	35.3	1.52	0.030	1.54	0.99-2.39
	D	0	0.0	1	100.0	-		-	
GOLD staging	Stage 1	5	71.4	2	28.6	Ref			
	Stage 2	51	44.3	64	55.7	0.62	0.067		
	Stage 3	74	44.8	91	55.2	0.62	0.067		
	Stage 4	29	45.3	35	54.7	0.63	0.098		
BMI (in kg/m ²)	Mean (SD)	20.5 (3.4)		19.8 (3.5)		0.97	0.067		
Post FEV1/FVC	Mean (SD)	56.1 (10.3)		55.7 (9.4)		0.99	0.783		
Post FVC	Mean (SD)	56.7 (11.7)		52.8 (12.9)		0.98	<0.001	0.98	0.97-0.99
Post FEV1	Mean (SD)	45.3 (15.7)		44.4 (16.8)		0.99	0.619		




Figure 1. Prevalence of suboptimal PIFR (<60 L/min) among COPD patients included in the study (N=351).